Key result
Sulfonylurea-related hypoglycemia in type 2 diabetes was associated with higher nocturnal QT dynamicity compared to subjects without hypoglycemia (0.193 vs. 0.159; P=0.01).
Why the study?
Does sulfonylurea-related hypoglycemia increase cardiac repolarization abnormalities and ectopy in patients with well-controlled type 2 diabetes?
Observational (n=30)
Does sulfonylurea-related hypoglycemia increase cardiac repolarization abnormalities and ectopy in patients with well-controlled type 2 diabetes?
Unrecognized hypoglycemia in well-controlled sulfonylurea-treated type 2 diabetes is associated with increased QT dynamicity and QTc prolongation, suggesting potential proarrhythmic cardiovascular sequelae.
Sulfonylurea hypoglycemia may promote nocturnal repolarization instability; hypothesis-generating for arrhythmia risk in type 2 diabetes.
OBJECTIVE To determine the effect of sulfonylurea-related hypoglycemia on cardiac repolarization and ectopy in the setting of well-controlled type 2 diabetes. RESEARCH DESIGN AND METHODS Thirty subjects with sulfonylurea-treated type 2 diabetes underwent 48 h of concurrent continuous glucose monitoring and ambulatory electrocardiography. Ventricular repolarization (QTc) and QT dynamicity were analyzed during periods of hypoglycemia (<3.5 mmol/L for >20 min) and compared with periods of euglycemia and hyperglycemia combined. Cardiac ectopy rates during hypoglycemia were compared with ectopy rates when blood glucose was 4–10 mmol/L. RESULTS Mean HbA1c was 6.9% (52 mmol/mol). Hypoglycemia was detected in 9 of 30 subjects (30%); episodes were typically nocturnal (67%) and asymptomatic (73%). Hypoglycemia-associated QTc prolongation was seen in five of nine subjects with a large variation in individual response. Higher QT dynamicity, a poor prognostic factor in cardiac disease, was seen in subjects who experienced hypoglycemia compared with subjects who did not (0.193 vs. 0.159 for the nocturnal period; P = 0.01). This finding persisted after the hypoglycemic event. The rates of ventricular and supraventricular ectopy demonstrated a nonsignificant trend toward an increase during hypoglycemia (median rate ratio 1.58 and 1.33, respectively). Similar, nonsignificant results were observed in a separate insulin-treated cohort. CONCLUSIONS Hypoglycemia, often unrecognized, is a frequent finding in well-controlled sulfonylurea-treated type 2 diabetes. It is associated with the novel finding of increased QT dynamicity and QTc prolongation in some individuals. Our findings suggest sulfonylurea-related hypoglycemia can have detrimental cardiovascular sequelae. Similar effects are also seen in the setting of insulin therapy.
No takes yet. Share an insight, caveat, or question.
Middleton et al. (2017) conducted an observational in Type 2 diabetes (n=30). Sulfonylurea-related hypoglycemia vs. Subjects who did not experience hypoglycemia was evaluated on QT dynamicity during the nocturnal period (p=0.01). Sulfonylurea-related hypoglycemia in type 2 diabetes was associated with higher nocturnal QT dynamicity compared to subjects without hypoglycemia (0.193 vs. 0.159; P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: